SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.

Trial Details

NCT ID
NCT05351788
Phase
PHASE2
Sponsor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SKB264
  • KL-A167
  • Carboplatin
  • Cisplatin
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Males or females ≥ 18 and ≤ 75 years of age at the time of signing the informed consent form;
  • Histologically and cytologically confirmed NSCLC;
  • Cohort 1: Patients with locally advanced/metastatic NSCLC with wild-type EGFR and negative ALK fusion gene, no or at most one prior line of systemi…
  • Provide fresh or archival tumor tissue for biomarker testing and analysis;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →